Email this page: News Release

Progenics Announces Positive Top-Line Results from Second Pivotal Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation; All Primary and Secondary Efficacy Endpoints Were Highly Statistically Significant

To (email address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your email address:   Copy yourself These email addresses will be used to email the page on your behalf and will not be used by Progenics Pharmaceuticals, Inc. for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps Progenics Pharmaceuticals, Inc. prevent automated submissions.